Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2680855rdf:typepubmed:Citationlld:pubmed
pubmed-article:2680855lifeskim:mentionsumls-concept:C0006837lld:lifeskim
pubmed-article:2680855lifeskim:mentionsumls-concept:C0009324lld:lifeskim
pubmed-article:2680855lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:2680855lifeskim:mentionsumls-concept:C0003261lld:lifeskim
pubmed-article:2680855lifeskim:mentionsumls-concept:C0022702lld:lifeskim
pubmed-article:2680855lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:2680855pubmed:issue4lld:pubmed
pubmed-article:2680855pubmed:dateCreated1989-12-7lld:pubmed
pubmed-article:2680855pubmed:abstractTextLevels of antibody against the mannan component of Candida albicans cell wall were determined and followed in 57 ulcerative colitis patients. The appearance of higher titers suggests an intermittent (benign) clinical course of the disease. Lower titer values at repeated checks are associated with a continuous (severe) clinical course. Our data suggest that Candida albicans antibody titer values may be used as an indicator of the clinical outcome of ulcerative colitis.lld:pubmed
pubmed-article:2680855pubmed:languageenglld:pubmed
pubmed-article:2680855pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2680855pubmed:citationSubsetIMlld:pubmed
pubmed-article:2680855pubmed:statusMEDLINElld:pubmed
pubmed-article:2680855pubmed:monthAuglld:pubmed
pubmed-article:2680855pubmed:issn0172-6390lld:pubmed
pubmed-article:2680855pubmed:authorpubmed-author:KissIIlld:pubmed
pubmed-article:2680855pubmed:authorpubmed-author:NagyFFlld:pubmed
pubmed-article:2680855pubmed:authorpubmed-author:SzöllösyEElld:pubmed
pubmed-article:2680855pubmed:authorpubmed-author:VarròVVlld:pubmed
pubmed-article:2680855pubmed:authorpubmed-author:SzènàsiZZlld:pubmed
pubmed-article:2680855pubmed:issnTypePrintlld:pubmed
pubmed-article:2680855pubmed:volume36lld:pubmed
pubmed-article:2680855pubmed:ownerNLMlld:pubmed
pubmed-article:2680855pubmed:authorsCompleteYlld:pubmed
pubmed-article:2680855pubmed:pagination182-4lld:pubmed
pubmed-article:2680855pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:meshHeadingpubmed-meshheading:2680855-...lld:pubmed
pubmed-article:2680855pubmed:year1989lld:pubmed
pubmed-article:2680855pubmed:articleTitleDetermination and kinetics of antibody response to Candida albicans in ulcerative colitis.lld:pubmed
pubmed-article:2680855pubmed:affiliationAlbert Szent-Györgyi University Medical School, 1st Department of Medicine, Szeged, Hungary.lld:pubmed
pubmed-article:2680855pubmed:publicationTypeJournal Articlelld:pubmed